Selective NKCC1 inhibitors for the treatment of brain disorders with defective chloride homeostasis
Proper intracellular Cl concentration is fundamental for physiological brain development and function. Accordingly, the aberrant expression of Cl importer NKCC1 and/or exporter KCC2 is implicated in several brain conditions, including autism spectrum disorders (ASD), Down syndrome (DS), and drug-resistant epilepsy (DRE). Interestingly, NKCC1 inhibition rescues core symptoms of these brain conditions in rodent models and/or clinical trials. However, current NKCC1 inhibitors have diuretic effects by also inhibiting the kidney Cl transporter NKCC2. These diuretic effects pose critical health conc